Premium
Ketanserin plus prostaglandin E1 (PGE‐1) as intracavernosal therapy for patients with erectile dysfunction unresponsive to PGE‐1 alone
Author(s) -
Mirone V.,
Imbimbo C.,
Fabrizio F.,
Longo N.,
Palmieri A.
Publication year - 1996
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1046/j.1464-410x.1996.97722.x
Subject(s) - prostaglandin e1 , erectile dysfunction , ketanserin , medicine , prostaglandin e , urology , combination therapy , prostaglandin , adverse effect , receptor , 5 ht receptor , serotonin
Objective To evaluate the treatment of patients with erectile dysfunction and who were unresponsive to intracavernosal injections of prostaglandin E‐1 (PGE‐1) alone with a combination of PGE‐1 and ketanserin, a peripheral vasodilator antagonizing 5‐hydroxytryptamine receptors and with mild alpha‐blocking effects. Patients and methods The study comprised 98 men with erectile dysfunction all of whom received an intracavernosal injection of 5–40 μg of PGE‐1. The 45 patients unresponsive to the maximum dose of 40 μg were selected for further treatment using a combined dose of 40 μg PGE‐1 and 2–7 mg of ketanserin. Their erectile response was assessed both subjectively, by interviewing the patient and their partner, and objectively using the ‘Rigiscan’ monitor. Results The combined therapy was effective in producing an erection sufficient for sexual intercourse in 34 (76%) of the patients. The combined dose was tolerated well and there were no adverse effects. Conclusions The results of this preliminary study suggest that the combination of PGE‐1 and ketanserin may be a therapeutic alternative to the implantation of a prosthesis in patients unresponsive to PGE‐1.